HRP20190343T1 - Novi kromon oksim derivat i njegova uporaba kao alosterni modulator metabotropnih receptora glutamata - Google Patents
Novi kromon oksim derivat i njegova uporaba kao alosterni modulator metabotropnih receptora glutamata Download PDFInfo
- Publication number
- HRP20190343T1 HRP20190343T1 HRP20190343TT HRP20190343T HRP20190343T1 HR P20190343 T1 HRP20190343 T1 HR P20190343T1 HR P20190343T T HRP20190343T T HR P20190343TT HR P20190343 T HRP20190343 T HR P20190343T HR P20190343 T1 HRP20190343 T1 HR P20190343T1
- Authority
- HR
- Croatia
- Prior art keywords
- disorders
- compound
- pharmaceutical composition
- disease
- condition
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Nutrition Science (AREA)
- Addiction (AREA)
- Virology (AREA)
- Rheumatology (AREA)
- Emergency Medicine (AREA)
- Physiology (AREA)
- Molecular Biology (AREA)
- Hospice & Palliative Care (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14182468 | 2014-08-27 | ||
| EP15770814.0A EP3186257B1 (en) | 2014-08-27 | 2015-08-27 | Novel chromone oxime derivative and its use as allosteric modulator of metabotropic glutamate receptors |
| PCT/EP2015/069601 WO2016030444A1 (en) | 2014-08-27 | 2015-08-27 | Novel chromone oxime derivative and its use as allosteric modulator of metabotropic glutamate receptors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20190343T1 true HRP20190343T1 (hr) | 2019-05-31 |
Family
ID=51421865
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20190343TT HRP20190343T1 (hr) | 2014-08-27 | 2015-08-27 | Novi kromon oksim derivat i njegova uporaba kao alosterni modulator metabotropnih receptora glutamata |
Country Status (26)
| Country | Link |
|---|---|
| US (3) | US10017521B2 (enExample) |
| EP (3) | EP3186257B1 (enExample) |
| JP (1) | JP6430015B2 (enExample) |
| KR (1) | KR101870589B1 (enExample) |
| CN (2) | CN106715444B (enExample) |
| AU (1) | AU2015308438B2 (enExample) |
| CA (1) | CA2956191C (enExample) |
| CY (1) | CY1121352T1 (enExample) |
| DK (1) | DK3186257T3 (enExample) |
| ES (1) | ES2714073T3 (enExample) |
| HR (1) | HRP20190343T1 (enExample) |
| HU (1) | HUE041941T2 (enExample) |
| IL (1) | IL250287B (enExample) |
| LT (1) | LT3186257T (enExample) |
| MA (3) | MA52702A (enExample) |
| ME (1) | ME03339B (enExample) |
| MX (1) | MX369643B (enExample) |
| NZ (1) | NZ728853A (enExample) |
| PL (1) | PL3186257T3 (enExample) |
| PT (1) | PT3186257T (enExample) |
| RS (1) | RS58592B1 (enExample) |
| RU (1) | RU2672569C2 (enExample) |
| SI (1) | SI3186257T1 (enExample) |
| SM (1) | SMT201900152T1 (enExample) |
| TR (1) | TR201903332T4 (enExample) |
| WO (1) | WO2016030444A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3186257B1 (en) * | 2014-08-27 | 2019-02-06 | Prexton Therapeutics SA | Novel chromone oxime derivative and its use as allosteric modulator of metabotropic glutamate receptors |
| WO2017032874A1 (en) * | 2015-08-27 | 2017-03-02 | Prexton Therapeutics Sa | Brain-penetrant chromone oxime derivative for the therapy of levodopa-induced dyskinesia |
| CA3102326A1 (en) | 2018-07-26 | 2020-01-30 | Domain Therapeutics | Substituted quinazolinone derivatives and their use as positive allosteric modulators of mglur4 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4065467A (en) | 1973-12-27 | 1977-12-27 | Carlo Erba, S. P. A. | 5:6-Benzo δ-pyrone derivatives and process for their preparation |
| US4777252A (en) | 1987-08-13 | 1988-10-11 | E. R. Squibb & Sons, Inc. | 2-oxo-1-[[(substituted sulfonyl)amino]-carbonyl]azetidines |
| JP3993651B2 (ja) * | 1994-10-21 | 2007-10-17 | アスビオファーマ株式会社 | シクロプロパクロメンカルボン酸誘導体 |
| EP1298129A3 (en) | 2001-09-28 | 2003-06-04 | Central Glass Company, Limited | Process for producing 4-sustituted benzopyran derivatives |
| MY141521A (en) | 2002-12-12 | 2010-05-14 | Hoffmann La Roche | 5-substituted-six-membered heteroaromatic glucokinase activators |
| WO2004092154A1 (en) | 2003-04-03 | 2004-10-28 | Vertex Pharmaceuticals Incorporated | Compositions useful as inhibitors of protein kinases |
| US20070027216A1 (en) | 2005-07-15 | 2007-02-01 | Bridget Larson | Novel hydrochloride salts of levodopa |
| US20100144756A1 (en) | 2007-07-13 | 2010-06-10 | Bolea Christelle | Novel heteroaromatic derivatives and their use as positive allosteric modulators of metabotropic glutamate receptors |
| GB0713686D0 (en) | 2007-07-13 | 2007-08-22 | Addex Pharmaceuticals Sa | New compounds 2 |
| WO2011051478A1 (en) | 2009-10-30 | 2011-05-05 | Domain Therapeutics | Novel oxime derivatives and their use as allosteric modulators of metabotropic glutamate receptors |
| PT3252057T (pt) | 2009-12-04 | 2024-06-04 | Sunovion Pharmaceuticals Inc | Compostos multicíclicos e métodos de utilização dos mesmos |
| US20140349994A1 (en) * | 2012-01-18 | 2014-11-27 | Addex Pharma S.A. | Novel 2-Amino-4,5,6,8-Tetrahydropyrazolo[3,4-b]Thiazolo [4,5-d]Azepine Derivatives and Their Use as Allosteric Modulators of Metabotropic Glutamate Receptors |
| EP3186257B1 (en) | 2014-08-27 | 2019-02-06 | Prexton Therapeutics SA | Novel chromone oxime derivative and its use as allosteric modulator of metabotropic glutamate receptors |
| WO2017032874A1 (en) | 2015-08-27 | 2017-03-02 | Prexton Therapeutics Sa | Brain-penetrant chromone oxime derivative for the therapy of levodopa-induced dyskinesia |
-
2015
- 2015-08-27 EP EP15770814.0A patent/EP3186257B1/en active Active
- 2015-08-27 LT LTEP15770814.0T patent/LT3186257T/lt unknown
- 2015-08-27 SI SI201530640T patent/SI3186257T1/sl unknown
- 2015-08-27 CA CA2956191A patent/CA2956191C/en not_active Expired - Fee Related
- 2015-08-27 MA MA052702A patent/MA52702A/fr unknown
- 2015-08-27 MA MA040530A patent/MA40530A/fr unknown
- 2015-08-27 DK DK15770814.0T patent/DK3186257T3/en active
- 2015-08-27 SM SM20190152T patent/SMT201900152T1/it unknown
- 2015-08-27 HR HRP20190343TT patent/HRP20190343T1/hr unknown
- 2015-08-27 US US15/506,941 patent/US10017521B2/en not_active Expired - Fee Related
- 2015-08-27 JP JP2017530425A patent/JP6430015B2/ja not_active Expired - Fee Related
- 2015-08-27 CN CN201580045432.7A patent/CN106715444B/zh not_active Expired - Fee Related
- 2015-08-27 AU AU2015308438A patent/AU2015308438B2/en not_active Ceased
- 2015-08-27 HU HUE15770814A patent/HUE041941T2/hu unknown
- 2015-08-27 WO PCT/EP2015/069601 patent/WO2016030444A1/en not_active Ceased
- 2015-08-27 EP EP19217991.9A patent/EP3696183A1/en not_active Withdrawn
- 2015-08-27 PL PL15770814T patent/PL3186257T3/pl unknown
- 2015-08-27 PT PT15770814T patent/PT3186257T/pt unknown
- 2015-08-27 MX MX2017002429A patent/MX369643B/es active IP Right Grant
- 2015-08-27 EP EP19151429.8A patent/EP3502115A1/en not_active Withdrawn
- 2015-08-27 KR KR1020177005768A patent/KR101870589B1/ko not_active Expired - Fee Related
- 2015-08-27 TR TR2019/03332T patent/TR201903332T4/tr unknown
- 2015-08-27 NZ NZ728853A patent/NZ728853A/en not_active IP Right Cessation
- 2015-08-27 ME MEP-2019-59A patent/ME03339B/me unknown
- 2015-08-27 CN CN201910567865.9A patent/CN110343118A/zh active Pending
- 2015-08-27 MA MA048048A patent/MA48048A/fr unknown
- 2015-08-27 ES ES15770814T patent/ES2714073T3/es active Active
- 2015-08-27 RU RU2017109818A patent/RU2672569C2/ru active
- 2015-08-27 RS RS20190289A patent/RS58592B1/sr unknown
-
2017
- 2017-01-25 IL IL250287A patent/IL250287B/en active IP Right Grant
-
2018
- 2018-06-05 US US16/000,338 patent/US10442818B2/en active Active
-
2019
- 2019-03-08 CY CY20191100277T patent/CY1121352T1/el unknown
- 2019-09-30 US US16/587,670 patent/US20200024285A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DOP2016000273A (es) | Compuesto de ciclopropanamina y sus usos. | |
| CL2014000806A1 (es) | Compuestos derivados de 1-arilcarbonil-4-oxi-piperidino; composicion farmaceutica que los comprende; uso para la prevencion o el tratamiento de enfermedades neurodegenerativas tales como enfermedad de alzheimer, enfermedad de parkinson, enfermedad de huntington o esclerosis multiple. | |
| UY35933A (es) | Composiciones farmacéuticas que comprenden azd9291 | |
| UY37617A (es) | Moduladores de la proteína reguladora de la conductancia transmembrana en fibrosis quística y métodos de empleo | |
| BR112018010018A2 (pt) | moduladores de ror-gama | |
| ECSP16070327A (es) | Heteroaril amidas como inhibidores de agregación de proteína | |
| HRP20201325T1 (hr) | Uporaba kanabidiola u liječenju kompleksa tuberozne skleroze | |
| BR112016004505A2 (pt) | uso de uma combinação de pelo menos torasemida e baclofeno, ou sais, pró-fármacos, derivados, ou formulações de liberação sustentada dos mesmos, uso de pelo menos torasemida e baclofeno, ou sais, pró-fármacos, derivados, ou formulações de liberação sustentada dos mesmos, e uso de uma composição compreendendo pelo menos torasemida e baclofeno, ou sais, pró-fármacos, derivados, ou formulações de liberação sustentada dos mesmos | |
| CO2019007830A2 (es) | Derivados de bis-heteroarilo bicíclicos como moduladores de agregación de proteínas | |
| MX357780B (es) | Derivados policíclicos, proceso para su preparación y su uso farmacéutico. | |
| CO6270332A2 (es) | Compuesto de alfa-(n-sulfonamido)acetamida novedoso como inhibidor de produccion de peptido beta amiloide | |
| BR112014005810A2 (pt) | formas sólidas de um inibidor da dissociação de transtirretina | |
| CO2019007835A2 (es) | Derivados de bis-heteroarilo como moduladores de la agregación de proteínas | |
| CY1124115T1 (el) | Η χρηση τριβενζοϊκου γλυκερυλιου που περιεχει συνθεση σε νευροεκφυλιστικες διαταραχες | |
| CO6382089A2 (es) | Compuestos,composiciones y metodos para el tratamiento de enfermadades causadas por un b-amiloide y sinucleinopatias | |
| SV2018005643A (es) | Composiciones de insulina de rapida accion | |
| CL2016000568A1 (es) | Compuestos derivados de 2h-indazol-2-il-n-hidroxi-2-metilsulfonil-2-metil-butanamida sustituidos o sus sales; sus composiciones farmacéuticas que los contiene y su uso para la prevención y/o tratamiento de infecciones bacterianas gram-negativas. | |
| BR112018001035A2 (pt) | compostos de fenoxiacetamidas aneladas, sal farmaceuticamente aceitável, seu método de síntese, combinação de medicamento e uso dos mesmos | |
| CO2019007833A2 (es) | Derivados de alcoxi bis-heteroarilo como moduladores de la agregación de proteínas | |
| RU2017109818A (ru) | Новое производное оксима хромона и его использование в качестве аллостерического модулятора метаботропных рецепторов глутамата | |
| PL2722322T3 (pl) | 1,3-Di-okso-indenowa pochodna, jej farmaceutycznie dopuszczalna sól lub izomer optyczny, sposób jej wytwarzania i kompozycja farmaceutyczna ją zawierająca jako przeciwwirusowy składnik czynny | |
| BR112017000762A2 (pt) | derivados de azaspiro(4.5)decano substituído. | |
| JP2017525776A5 (enExample) | ||
| BR112018012616A2 (pt) | formulação galênica que compreende um fármaco tópico | |
| EP3326628A4 (en) | PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION WITH HIGH-CONCENTRATED TAXAN |